Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1861 • ACR Convergence 2024
CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice
Yuzo Koda¹, Piruzyan Mariam¹, Sota Fujimori¹, Ryota Sato² and Sayuka Kato¹, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Brighton, MA
Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…
Abstract Number: 2297 • ACR Convergence 2024
Mortality and Its Predictor Variables in Patients with Sjögren Disease: Data from SjögrenSER-Pros Prospective Registry
Olga Rusinovich¹, Zulema Plaza², Mónica Fernández Castro³, José Rosas-Gómez de Salazar⁴, Victor Manuel Martinez Taboada⁵, Alejandro Olive⁶, Raúl Menor Almagro⁷, Belen Serrano Benavente⁸, Judit Font Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesus A García-Vadillo¹², Ruth Lopez Gonzalez¹³, Javier Narvaez-García¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Gonzalez Martin¹⁷, Paloma Vela-Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, MARIA BEATRIZ PAREDES ROMERO²¹, ELENA Aurrecoechea²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Heredia Martin²⁵, Clara Moriano²⁶, Maria Angeles Blazquez Canamero²⁷, Paula Estrada-Alarcón²⁸, enrique Judez²⁹, Joaquin María Belzunegui:³⁰, Consuelo Ramos³¹, Marta de la Puerta³², Fernando Sánchez-Alonso³³ and Jose Luis Andreu³⁴, ¹Hospital Universitario Puerta de Hierro Majadahonda., Boadilla del Monte, Spain, ²Fundacion Española de Reumatología, Madrid, Spain, ³Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Cantabria, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ⁷Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ⁸Hospital Gregorio Marañón, Madrid, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ¹²H La Princesa, Madrid, Spain, ¹³Complejo Hospitalario de Zamora, Zamora, Castilla y Leon, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵H Universitario de Canarias, La Laguna- Tenerife, Canarias, Spain, ¹⁶Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁷H Madrid Norte SanChinarro, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Spain, ¹⁹Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ²⁰Gob Canarias, Tenerife, Canarias, Spain, ²¹H Infanta Sofia, Madrid, Spain, ²²HOSPITAL SIERRALLANA, CANTABRIA, Spain, ²³12 de Octubre University Hospital, Madrid, Spain, ²⁴Galicia Health Service (SERGAS), Vigo, Spain, ²⁵Hospital de L’Hospitalet, Barcelona, Spain, ²⁶Hospital León, LEON, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Madrid, Spain, ²⁸Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁹H de Albacete, Albacete, Spain, ³⁰H de Donostia, Donostia-San Sebasti, Spain, ³¹Hospital Universitario Virgen de Valme, Sevilla, Spain, ³²Spanish Society of Rheumatology, Madrid, Spain, ³³Sociedad Española de Reumatología, Madrid, Spain, ³⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: It remains debated if patients with Sjögren´s disease (SjD) have a greater mortality risk. The objective of our study was to determine the magnitude…
Abstract Number: 2530 • ACR Convergence 2024
Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis
Theodoros Ioannis Papadimitriou¹, Prashant Singh², Arjan van Caam³, Madelon Vonk⁴, Irene E. van der Horst-Bruinsma⁵, Peter van der kraan³, Erik Aarntzen⁶, Martijn Huijnen⁷, Hans Koenen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ³Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, ⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands
Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
Abstract Number: 1130 • ACR Convergence 2024
Safety of Bispecific T-cell Engager Therapy in Autoimmune Disease
Melanie Hagen¹, Laura Bucci¹, Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: B-cells and plasma cells are key drivers of systemic autoimmune diseases (AID). Recent data demonstrated preliminary safety and efficacy of using the CD3xCD19 bispecific…
Abstract Number: 1420 • ACR Convergence 2024
Alignment Between Rheumatology and Neurology of Nomenclature for Peripheral Nervous System Neuropathies
Ghaith Noaiseh¹, George Sarka², Anahita Deboo³, Arun Varadhachary⁴, Robert Fox⁵, Matthew Baker⁶, Stamatina Danielides⁷, Eduardo de Sousa⁸, Julie Frantsve Hawley⁹, Brent Goodman¹⁰, Katherine Hammitt⁹, Jennifer King¹¹, Steven Mandel¹², Pantelis Pavlakis¹³, Daniel Wallace¹⁴, Robert Hal Scofield¹⁵, Nancy Carteron¹⁶ and Steven Carsons¹⁷, ¹University of Kansas Medical Center, Kansas City, KS, ²UCLA, Laguna Hills, CA, ³Temple University, Philadelphia, ⁴Washington University in St. Louis, St. Louis, MO, ⁵Rheumatology Clinic, San Diego, CA, ⁶Stanford University, Menlo Park, CA, ⁷Vcu, Glen Allen, VA, ⁸Mercy, Moore, OK, ⁹Sjogren's Foundation, Reston, VA, ¹⁰Mayo Clinic, Scottsdale, AZ, ¹¹UCLA, Los Angeles, CA, ¹²Hofstra, Hempstead, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Cedars Sinai Medical Center, Studio City, CA, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of California, Berkeley & San Francisco, Angwin, CA, ¹⁷NYU Long Island School of Medicine, Mineola, NY
Background/Purpose: The Sjögren’s Foundation Clinical Practice Guidelines for Peripheral Nervous System (PNS) diagnosis, management and treatment in Sjögren’s brought to the fore a major issue…
Abstract Number: 1866 • ACR Convergence 2024
Identification of Sjögren’s Disease-Associated CD4+ T Cell Receptor (TCR) Motifs and Repertoire Landscape Through TCR Deep Sequencing
Ananth Aditya Jupudi¹, Michelle L. Joachims², Christina Lawrence², Charmaine Lopez-Davis², Bhuwan Khatri², Astrid Rasmussen², Kiely Grundahl², Robert Hal Scofield², Judith James², Joel Guthridge², Christopher Lessard², Linda F. Thompson² and A. Darise Farris², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s disease (SjD) is a chronic rheumatic autoimmune disorder characterized by focal lymphocytic infiltration of the lacrimal and salivary glands (SG). CD4+ T cells…
Abstract Number: 2298 • ACR Convergence 2024
Fibroblast-driven Ttek Activation May Drive Acinar Cell Dysfunction in Sjögren’s Disease, Prior to Lymphocytic Infiltration
Ting Yang¹, Rick Wilbrink¹, Janneke Terpstra¹, Silvia Liefers², Arjan Vissink¹, Fred Spijkervet¹, Hendrika Bootsma³, Frans Kroese⁴ and Sarah Pringle⁴, ¹UMCG, Groningen, Netherlands, ²University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, ³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ⁴University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Lymphocytic infiltration of the salivary glands (SGs) represents one hallmark of the autoimmune conditions Sjögren’s Disease (SjD). It is becoming apparent however that loss…
Abstract Number: 2537 • ACR Convergence 2024
Sjögren’s Disease and Non-Sjögren’s Sicca Patient Subsets Exhibit Cell Type-specific Transcriptional Dysregulations That May Identify Early Molecular Predictors of Disease Transition
James Li¹, Chuang Li², Bhuwan Khatri², Anna Stolarczyk², Kandice Tessneer², Astrid Rasmussen², Joel Guthridge², Judith James², Robert Hal Scofield², He Li³, A. Darise Farris², Kathy Sivils⁴ and Christopher Lessard², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁴Johnson & Johnson Innovative Medicine, Edmond, OK
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disorder characterized by inflammatory destruction of the exocrine glands. SjD heterogeneity has been described through the presence or…
Abstract Number: L10 • ACR Convergence 2023
Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement
E. William St. Clair¹, Liangwei Wang², Ilias Alevizos², William A. Rees², Alan N. Baer³, Wan-Fai Ng⁴, Ghaith Noaiseh⁵ and Chiara Baldini⁶, ¹Department of Medicine, Duke University Medical Center, Durham, NC, USA, Durham, NC, ²Horizon Therapeutics plc, Rockville, MD, ³Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, Baltimore, MD, ⁴Translational and Clinical Research Institute, Newcastle University, Newcastle, United Kingdom, ⁵Division of Allergy, Clinical Immunology and Rheumatology, Department of Medicine, University of Kansas, Kansas City, KS, USA, Kansas CIty, KS, ⁶Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Dazodalibep (DAZ) is a non-antibody fusion protein that acts as a CD40L antagonist and blocks costimulatory signals between immune cells, including T cells, B…
Abstract Number: L18 • ACR Convergence 2023
Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands
Xiaobing Wang¹, Jing Luo², Senhong Ying³, Jingwei Hong⁴, Hui Cheng⁴, Ping Wang⁴, Yanran He⁵, Wenjing Ye⁶, Xiaofang Zhu⁷, Chengwei Zhu⁸, Langxiong Yang², Zhongshan Li⁹, Suxian Lin¹⁰, Dan Chen⁷, Xin Wu¹¹, Zhengwei Xie¹², Jinyu Wu¹³ and Huji Xu¹, ¹Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University, Shanghai, China, ²School of Medicine, Tsinghua University, Beijing, China, ³Precision Medicine Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China, ⁴Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁵Committee on Cancer Biology, University of Chicago, Chicago, IL, ⁶Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, ⁷Rheumatology Department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁸Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, ⁹Wenzhou Medical University, Wenzhou, China, ¹⁰Rheumatology Department, Wenzhou People's Hospital, Wenzhou, China, ¹¹Department of Rheumatology and Immunology,Changzheng Hospital, Naval Medical University, Shanghai, China, ¹²Peking University International Cancer Institute, Health Science Center, Peking University, Beijing, China, ¹³Institute of Genomic Medicine, Key Laboratory of Laboratory Medicine, Ministry of Education, Wenzhou Medical University, Wenzhou, China
Background/Purpose: Primary Sjögren's syndrome (pSS) is a complex autoimmune disease with significant heterogeneity. Our study aimed to clarify the etiology and molecular variation of the…
Abstract Number: 0008 • ACR Convergence 2023
Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice
Biji T Kurien¹, Devavrat Dave¹, Martha Tsaliki¹, Valerie Lewis¹ and R Hal Scofield², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren's Disease is an autoimmune condition in which patients exhibit decreased salivary/lacrimal gland function and express autoantibodies that target the 60k molecular weight Ro…
Abstract Number: 1251 • ACR Convergence 2023
Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital
Maya Faison¹, Catherine Lavallee², Joseph McDonald¹ and Cuoghi Edens¹, ¹University of Chicago Medicine, Chicago, IL, ²Virginia Tech Carilion School of Medicine, Roanoke, VA
Background/Purpose: The prevalence of Sjogren's disease (SD) is becoming increasingly recognized in pediatric rheumatology. Despite fewer sicca symptoms, it has been shown that pediatric SD…
Abstract Number: 1378 • ACR Convergence 2023
The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study
Gaetano La Rocca¹, Francesco Ferro², Elena Elefante³, Silvia Fonzetti⁴, Giovanni Fulvio⁵, Inmaculada Conception Navarro Garcia³, Chiara Romei⁶, Marta Mosca³ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴AOUP, Pisa, Italy, ⁵University of Pisa, Pisa, Italy, ⁶Department of Diagnostic Imaging, Diagnostic Radiology 2, Pisa University Hospital, Pisa, Italy
Background/Purpose: In clinical trials investigating new drugs for the management of Interstitial Lung Disease (ILD) patient reported outcomes (PRO) are increasingly employed as outcome measures…
Abstract Number: 2179 • ACR Convergence 2023
Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey
Sara McCoy¹, Alan Baer², Ann Xi³, Corey Moorhead⁴, Giorgio Castellano⁴, Anthony Amatucci⁵, Ilias Alevizos⁶ and Haridarshan Patel⁷, ¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Horizon Therapeutics, Indianapolis, IN, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Horizon Therapeutics, Cambridge, MA, ⁶Horizon Therapeutics, Rockville, MD, ⁷Horizon Therapeutics, Deerfield, IL
Background/Purpose: Sjögren's disease (SjD) is a debilitating disease that has been shown to impact patients' quality of life (QoL). Though oral and ocular dryness are…
Abstract Number: 2260 • ACR Convergence 2023
Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Yuichiro fujieda¹, Kodai Sakiyama¹, Nobuya Abe¹, Ryo Hisada¹, Michihito Kono¹, Masaru Kato¹, Olga Amengual², Khin Khin Tha³, Hisashi Shirakawa⁴ and Tatsuya Atsuma⁵, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ³Global Center for Biomedical Science and Engineering, Faculty of Medicine, Hokkaido University Hospital, Sapporo, Japan, ⁴Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, Kyoto, Japan, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan
Background/Purpose: Fatigue is a common symptom in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS). Resting-state functional magnetic resonance imaging (rs-fMRI) has…

« Previous Page
1
…
4
5
6
7
8
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.